EUVIMEDEUVIMED entdecken
Crossref

Recent Synthetic and Anticancer Perspectives of Isatin‐Schiff Base Derivatives: An Overview

Shivani Rawat, Vikrant Abbot, Kapil Kumar

ChemistrySelect · 2026-01 · 11 (2)

DOI: 10.1002/slct.202505466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 09.01.2026. Verfasst von Shivani Rawat und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: University of Petroleum and Energy Studies.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is a major challenge for the scientific community in the 21 st century, contributing significantly to high socio‐economic and public health concerns, with an estimated 35 million new cases by 2050. Several internal or external factors account for genetic changes causing disruption of the normal cell cycle. Multiple drug resistance (MDR) and various side effects are expressed by available antineoplastic drugs. The nitrogen‐containing aromatic heterocyclic compound isatin, commonly known as 1 H ‐indole‐2,3‐dione, has great biological potential with diverse therapeutic applications. Erdmann and Laurent found isatin initially from the oxidation of indigo dye in 1841. Food and Drug Administration (FDA)‐approved drugs sunitinib and nintedanib (tyrosine kinase inhibitors), used in lung and renal cell carcinoma, have potentiated attention to isatins as a novel class of antineoplastic agents. Schiff bases, a biologically active linker, have helped chemists to synthesize metal complexes and novel cytotoxic isatin hybrids. Based on the past 12 years of published papers on isatin Schiff bases, the current study has summarized the anticancer potential of isatin Schiff's hybrids and metal complexes. The review aimed to cover various aspects, like synthetic scheme, structure–activity relationship (SAR) analysis, including docking, which will help in the successful development of safer and less toxic anticancer agents with enhanced target selectivity to overcome MDR.

Förderung

  • University of Petroleum and Energy Studies

Zitieren

APA

Rawat, S., Abbot, V., & Kumar, K. (2026). Recent Synthetic and Anticancer Perspectives of Isatin‐Schiff Base Derivatives: An Overview. ChemistrySelect, 11(2). https://doi.org/10.1002/slct.202505466

Vancouver

Rawat S, Abbot V, Kumar K. Recent Synthetic and Anticancer Perspectives of Isatin‐Schiff Base Derivatives: An Overview. ChemistrySelect. 2026;11(2). doi:10.1002/slct.202505466

BibTeX
@article{Rawat2026,
  author = {Rawat, Shivani and Abbot, Vikrant and Kumar, Kapil},
  title = {Recent Synthetic and Anticancer Perspectives of Isatin‐Schiff Base Derivatives: An Overview},
  journal = {ChemistrySelect},
  year = {2026},
  volume = {11},
  number = {2},
  doi = {10.1002/slct.202505466}
}
Kostenlos starten →